The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
复制标题
DOI：
10.1007/s10549-018-4834-7
复制
发表时间：
2018-09
影响因子：
3.8
通讯作者：
Fiering S
中科院分区：
文献类型：
--
作者：
Arias-Pulido H;Cimino-Mathews A;Chaher N;Qualls C;Joste N;Colpaert C;Marotti JD;Foisey M;Prossnitz ER;Emens LA;Fiering S
评价PD-L1和CD 20的蛋白表达作为炎性乳腺癌（IBC）样本中患者结局的预后生物标志物。通过免疫组织化学法测定221例预处理IBC活检组织中PD-L1和CD 20蛋白表达。在肿瘤细胞（PD-L1+肿瘤细胞）和肿瘤间质浸润淋巴细胞（PD-L1+ TIL）中评估PD-L1;在肿瘤浸润B细胞中对CD 20进行评分。生存分析采用Kaplan-Meier曲线和考克斯比例风险模型。IBC中PD-L1+肿瘤细胞、PD-L1+ TIL和CD 20 + TIL的检出率分别为8%、66%和62%。PD-L1+肿瘤细胞与高TIL、病理学完全缓解（pCR）、CD 20 + TIL密切相关，但与乳腺癌特异性生存期轻微相关（BCSS，P=0.057）。在所有IBC和三阴性（TN）IBC中，PD-L1+ TILs与高TILs、CD 20 + TILs和更长的无病生存期（DFS）密切相关（P<0.035）。肿瘤中同时含有CD 20 + TIL和PD-L1+ TIL（CD 20 + TIL/PD-L1+ TIL）的IBC和TN IBC患者显示，与缺乏两者或仅含有CD 20 + TIL或PD-L1+ TIL的患者相比，DFS更长，BCSS改善（P<0.002）。在多变量分析中，CD 20 +TILs/PD-L1+TILs状态是IBC患者DFS的独立预后因素（风险比（HR）：0.53，95% CI 0.37-0.77）和TN IBC（HR：0.39 95% CI 0.17-0.88），IBC中BCSS（HR：0.60 95% CI 0.43-0.85）和TN IBC（HR：0.38 95% CI 0.17-0.83）。CD 20 +TILs/PD-L1+TILs状态代表了IBC和TN IBC中的独立有利预后因素，表明B细胞在抗肿瘤免疫应答中的关键作用。抗PD-1/PD-L1和B细胞活化免疫疗法应在这些情况下进行探索。
To evaluate protein expression of PD-L1 and CD20 as prognostic biomarkers of patient outcome in inflammatory breast cancer (IBC) samples. PD-L1 and CD20 protein expression was measured by immunohistochemistry in 221 pretreatment IBC biopsies. PD-L1 was assessed in tumor cells (PD-L1+ tumor cells) and tumor stromal infiltrating lymphocytes (PD-L1+ TILs); CD20 was scored in tumor-infiltrating B cells. Kaplan–Meier curves and Cox proportional hazard models were used for survival analysis. PD-L1+ tumor cells, PD-L1+ TILs, and CD20+ TILs were found in 8%, 66%, and 62% of IBC, respectively. PD-L1+ tumor cells strongly correlated with high TILs, pathological complete response (pCR), CD20+ TILs, but marginally with breast cancer-specific survival (BCSS, P=0.057). PD-L1+ TILs strongly correlated with high TILs, CD20+ TILs, and longer disease-free survival (DFS) in all IBC and in triple-negative (TN) IBC (P<0.035). IBC and TN IBC patients with tumors containing both CD20+ TILs and PD-L1+ TILs (CD20+TILs/PD-L1+TILs) showed longer DFS and improved BCSS (P<0.002) than patients lacking both, or those with either CD20+ TILs or PD-L1+ TILs alone. In multivariate analyses, CD20+TILs/PD-L1+TILs status was an independent prognostic factor for DFS in IBC (hazard ratio (HR): 0.53, 95% CI 0.37–0.77) and TN IBC (HR: 0.39 95% CI 0.17–0.88), and for BCSS in IBC (HR: 0.60 95% CI 0.43–0.85) and TN IBC (HR: 0.38 95% CI 0.17–0.83). CD20+TILs/PD-L1+TILs status represents an independent favorable prognostic factor in IBC and TN IBC, suggesting a critical role for B-cells in anti-tumor immune responses. Anti-PD-1/PD-L1 and B-cell-activating immunotherapies should be explored in these settings.
登录
查看更多内容
影响因子：
3.5
作者：
He, Jing;Huo, Lei;Gong, Yun
通讯作者：
Gong, Yun
影响因子：
--
作者：
Sabatier R;Finetti P;Mamessier E;Adelaide J;Chaffanet M;Ali HR;Viens P;Caldas C;Birnbaum D;Bertucci F
通讯作者：
Bertucci F
影响因子：
45.3
作者：
Nanda, Rita;Chow, Laura Q. M.;Buisseret, Laurence
通讯作者：
Buisseret, Laurence
影响因子：
10.3
作者：
Hance, KW;Anderson, WF;Levine, PH
通讯作者：
Levine, PH
影响因子：
45.3
作者：
Mahmoud, Sahar M. A.;Paish, Emma Claire;Green, Andrew R.
通讯作者：
Green, Andrew R.